ASH 2020 | Nanatinostat and valganciclovir for EBV-associated lymphoma
Pierluigi Porcu, MD, Sidney Kimmel Cancer Center, Philadelphia, PA, reports safety and efficacy findings of the Phase II trial (NCT03397706) evaluating nanatinostat and valganciclovir in patients with EBV positive lymphomas. The Phase II results confirm the combination was well tolerated, with no additional adverse events reported. The most common adverse events (AE) associated with the combination was reversible cytopenia, including thrombocytopenia, which was reported in the Phase I study. The regimen showed efficacy in various subgroups of EBV-associated lymphomas, including diffuse large B-cell lymphoma (DLBCL), and immunodeficiency-associated lymphoproliferative disorders (IA-LPD). However, overall response (OR) and complete response (CR) rates were particularly encouraging in patients with EBV-positive T/NK-cell lymphoma. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
